The Cancer Letter

Inside information on cancer research and drug development

Clinical Roundup

Lasofoxifene + abemaciclib shows potential in ER+/HER2− breast cancer with ESR1 mutation

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

Updated data have emerged from the ELAINE-2 clinical trial of lasofoxifene plus abemaciclib in women with locally advanced or metastatic ER+/HER2− breast cancer and an ESR1 mutation after progression on prior therapies. 

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

In Brief

Tari King appointed chief surgical officer for cancer service line, co-director of Glenn Family Breast Center at Winship, chief of Division of Breast Surgery at Emory

Breast cancer surgeon Tari A. King was appointed as chief surgical officer for the cancer service line at Winship Cancer Institute of Emory University and Emory Healthcare. Joining Emory on July 14, she will also be the chief of the newly formed Division of Breast Surgery in the Department of Surgery at Emory University School of Medicine and co-director of Winship’s Glenn Family Breast Center.
Table of Contents

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account